In vitro cytotoxic effect of PARP inhibitor alone and in combination with nab‑paclitaxel on triple‑negative and luminal A breast cancer cells

Topçul,Mehmet; Çeti̇n,İdi̇l; Özbaş Turan,Suna; Kolusayin Ozar,Melek   Özlem

doi:10.3892/or.2018.6364

In vitro cytotoxic effect of PARP inhibitor alone and in combination with nab‑paclitaxel on triple‑negative and luminal A breast cancer cells

Authors:
- Mehmet Topçul
- İdi̇l Çeti̇n
- Suna Özbaş Turan
- Melek Özlem Kolusayin Ozar
View Affiliations

Affiliations: Department of Biology, Faculty of Science, Istanbul University, Vezneciler, Istanbul 34459, Turkey, Faculty of Pharmacy, Marmara University, Haydarpaşa, Istanbul 34668, Turkey, Department of Forensic Science, Cerrahpaşa Medical Faculty, Istanbul University, Fatih, Istanbul 34098, Turkey
Published online on: April 12, 2018 https://doi.org/10.3892/or.2018.6364
Pages: 527-535

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

In the present study, the in vitro cytotoxic effect of poly(ADP‑ribose) polymerase (PARP) inhibitor alone and in combination with nab‑paclitaxel was evaluated on human triple‑negative breast cancer (TNBC) cell line MDA‑MB‑231 and human luminal A breast cancer cell line MCF‑7. For this purpose, cell index (CI) values obtained from xCELLigence Real‑Time Cell Analysis (RTCA) DP instrument, mitotic index (MI), labelling index (LI) and apoptotic index (AI) analysis among cell kinetic parameters were used. As a result of PARP inhibitor application, there was a significant decrease in CI, MI and LI and a significant increase in AI for all the experimental groups. After application of PARP inhibitor in combination with nab‑paclitaxel, the CI values were decreased for both cell lines, and the differences between the control and all the experimental groups were statistically significant (P<0.01) for all applications. PARP inhibitor, alone or in combination with nab‑paclitaxel offers a promising treatment modality in different breast cancer subtypes.

View Figures

View References

1	Sørlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, Deng S, Johnsen H, Pesich R, Geisler S, et al: Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA. 100:8418–8423. 2003. View Article : Google Scholar : PubMed/NCBI
2	Cheang MC, Chia SK, Voduc D, Gao D, Leung S, Snider J, Watson M, Davies S, Bernard PS, Parker JS, et al: Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst. 101:736–750. 2009. View Article : Google Scholar : PubMed/NCBI
3	Cetin I and Topcul M: Triple negative breast cancer. Asian Pac J Cancer Prev. 15:2427–2431. 2014. View Article : Google Scholar : PubMed/NCBI
4	Rouleau M, Patel A, Hendzel MJ, Kaufmann SH and Poirier GG: PARP inhibition: PARP1 and beyond. Nat Rev Cancer. 10:293–301. 2010. View Article : Google Scholar : PubMed/NCBI
5	Weil MK and Chen AP: PARP inhibitor treatment in ovarian and breast cancer. Curr Probl Cancer. 35:7–50. 2011. View Article : Google Scholar : PubMed/NCBI
6	Ibrahim NK, Desai N, Legha S, Soon-Shiong P, Theriault RL, Rivera E, Esmaeli B, Ring SE, Bedikian A, Hortobagyi GN, et al: Phase I and pharmacokinetic study of ABI-007, a Cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel. Clin Cancer Res. 8:1038–1044. 2002.PubMed/NCBI
7	ten Tije AJ, Verweij J, Loos WJ and Sparreboom A: Pharmacological effects of formulation vehicles: Implications for cancer chemotherapy. Clin Pharmacokinet. 42:665–685. 2003. View Article : Google Scholar : PubMed/NCBI
8	Gradishar WJ, Tjulandin S, Davidson N, Shaw H, Desai N, Bhar P, Hawkins M and O'Shaughnessy J: Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol. 23:7794–7803. 2005. View Article : Google Scholar : PubMed/NCBI
9	Reis-Filho JS and Tutt ANJ: Triple negative tumours: A critical review. Histopathology. 52:108–118. 2008. View Article : Google Scholar : PubMed/NCBI
10	Saha P and Nanda R: Concepts and targets in triple-negative breast cancer: Recent results and clinical implications. Ther Adv Med Oncol. 8:351–359. 2016. View Article : Google Scholar : PubMed/NCBI
11	Topcul M and Cetin I: Endpoint of cancer treatment: Targeted therapies. Asian Pac J Cancer Prev. 15:4395–4403. 2014. View Article : Google Scholar : PubMed/NCBI
12	Rouzier R, Perou CM, Symmans WF, Ibrahim N, Cristofanilli M, Anderson K, Hess KR, Stec J, Ayers M, Wagner P, et al: Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res. 11:5678–5685. 2005. View Article : Google Scholar : PubMed/NCBI
13	Carey LA, Dees EC, Sawyer L, Gatti L, Moore DT, Collichio F, Ollila DW, Sartor CI, Graham ML and Perou CM: The triple negative paradox: Primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res. 13:2329–2334. 2007. View Article : Google Scholar : PubMed/NCBI
14	O'Shaughnessy J, Yoffe M, Osborne C, Blum J, Rocha C, Ossovskaya V, Sherman B and Bradley C: Triple negative breast cancer: A phase 2, multi-center, open-label, randomized trial of gemcitabine/carboplatin (G/C), with or without BSI-201, a PARP inhibitor. Cancer Res. 69 Suppl:21202009. View Article : Google Scholar
15	Dent RA, Lindeman GJ, Clemons M, Wildiers H, Chan A, McCarthy NJ, Singer CF, Lowe ES, Watkins CL and Carmichael J: Phase I trial of the oral PARP inhibitor olaparib in combination with paclitaxel for first- or second-line treatment of patients with metastatic triple-negative breast cancer. Breast Cancer Res. 15:R882013. View Article : Google Scholar : PubMed/NCBI
16	Graziani G and Szabó C: Clinical perspectives of PARP inhibitors. Pharmacol Res. 52:109–118. 2005. View Article : Google Scholar : PubMed/NCBI
17	Hastak K, Alli E and Ford JM: Synergistic chemosensitivity of triple-negative breast cancer cell lines to poly(ADP-Ribose) polymerase inhibition, gemcitabine, and cisplatin. Cancer Res. 70:7970–7980. 2010. View Article : Google Scholar : PubMed/NCBI
18	Jacob DA, Bahra M, Langrehr JM, Boas-Knoop S, Stefaniak R, Davis J, Schumacher G, Lippert S and Neumann UP: Combination therapy of poly (ADP-ribose) polymerase inhibitor 3-aminobenzamide and gemcitabine shows strong antitumor activity in pancreatic cancer cells. J Gastroenterol Hepatol. 22:738–748. 2007.PubMed/NCBI
19	Schiff PB and Horwitz SB: Taxol stabilizes microtubules in mouse fibroblast cells. Proc Natl Acad Sci USA. 77:1561–1565. 1980. View Article : Google Scholar : PubMed/NCBI
20	Jordan MA and Wilson L: Microtubules and actin filaments: Dynamic targets for cancer chemotherapy. Curr Opin Cell Biol. 10:123–130. 1998. View Article : Google Scholar : PubMed/NCBI
21	Jordan MA, Toso RJ, Thrower D and Wilson L: Mechanism of mitotic block and inhibition of cell proliferation by taxol at low concentrations. Proc Natl Acad Sci USA. 90:9552–9556. 1993. View Article : Google Scholar : PubMed/NCBI
22	Crown J and O'Leary M: The taxanes: An update. Lancet. 355:1176–1178. 2000. View Article : Google Scholar : PubMed/NCBI
23	Kratz F: Albumin as a drug carrier: Design of prodrugs, drug conjugates and nanoparticles. J Control Release. 132:171–183. 2008. View Article : Google Scholar : PubMed/NCBI
24	Untch M, Jackisch C, Schneeweiss A, Conrad B, Aktas B, Denkert C, Eidtmann H, Wiebringhaus H, Kümmel S, Hilfrich J, et al: German Breast Group (GBG); Arbeitsgemeinschaft Gynäkologische Onkologie-Breast (AGO-B) Investigators: Nab-paclitaxel versus solvent-based paclitaxel in neoadjuvant chemotherapy for early breast cancer (GeparSepto-GBG 69): A randomised, phase 3 trial. Lancet Oncol. 17:345–356. 2016. View Article : Google Scholar : PubMed/NCBI
25	Giaccone G, Rajan A, Kelly RJ, Gutierrez M, Kummar S, Yancey M, Ji JJ, Zhang Y, Parchment RE and Doroshow JH: A phase I combination study of olaparib (AZD2281; KU-0059436) and cisplatin (C) plus gemcitabine (G) in adults with solid tumors. J Clin Oncol. 28 suppl 15:30272010. View Article : Google Scholar
26	Haince JF, Kozlov S, Dawson VL, Dawson TM, Hendzel MJ, Lavin MF and Poirier GG: Ataxia telangiectasia mutated (ATM) signaling network is modulated by a novel poly(ADP-ribose)-dependent pathway in the early response to DNA-damaging agents. J Biol Chem. 282:16441–16453. 2007. View Article : Google Scholar : PubMed/NCBI
27	Kang B, Guo RF, Tan XH, Zhao M, Tang ZB and Lu YY: Expression status of ataxia-telangiectasia-mutated gene correlated with prognosis in advanced gastric cancer. Mutat Res. 638:17–25. 2008. View Article : Google Scholar : PubMed/NCBI
28	Cetin I and Topcul MR: In vitro antiproliferative effects of nab-paclitaxel with liposomal cisplatin on MDA-MB-231 and MCF-7 breast cancer cell lines. J BUON. 22:347–354. 2017.PubMed/NCBI